Sulfadiazine Sodium

(Sulfadiazine)

ApprovedSmall molecule

Sulfadiazine Sodium is one of 25 small molecule programs targeting Congenital Toxoplasmosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Congenital ToxoplasmosisActive, not recruiting

EncephalitisActive, not recruiting

Congenital ToxoplasmosisApproved

Active, not recruiting

EncephalitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Encephalitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Decadron

AAspen Global Incorporated

Approved

2 3

ENSPRYNG

Roche

Phase 3

—4

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

1 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

1 6

Sulfadiazine Sodium

Eli Lilly

Approved

1 7

Immunoglobulins

CSL Behring

Phase 3

1 8

Rituxan

Roche

Phase 2

2 9

Biaxin

AbbVie

Phase 2

1 10

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Post-ApprovalRecruiting

Congenital Toxoplasmosis

NCT00004317

Clinical

Trials by Indication[1]

Encephalitis1 trial

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000794·100 enrolled

Congenital Toxoplasmosis1 trial

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00004317·600 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

SULFADIAZINE SODIUM

NDA NDA004054

Jan 1, 1982

SULFADIAZINE

NDA NDA004125

Jan 1, 1982

SULFADIAZINE

NDA NDA004122

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sulfadiazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfadiazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfadiazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA004054). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

Sulfadiazine Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Encephalitis1 trial

Congenital Toxoplasmosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News